SCHEMBL2260765

SCHEMBL2260765

CS(=O)(=O)Nc1cc(C(=O)O)cc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4D Q6B0I6 1/20 0.40
EGLN1 Q9GZT9 1/20 0.38
WDR5 P61964 1/20 0.38
NEU3 Q9UQ49 1/20 0.38
TPMT P51580 2/20 0.37
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HIF1A Q16665 1/20 0.36
SCN9A Q15858 1/20 0.36
POLB P06746 1/20 0.36
MMP2 P08253 1/20 0.35
TTR P02766 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PIK3CG P48736 1/20 0.34
CXCR2 P25025 1/20 0.34
IGFBP3 P17936 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257869 0.86 POLB (0.48) SCN9APOLBKMT2AKDM4ESMN1; SMN2
SCHEMBL23000032 0.82 KDM4D (0.40) KDM4DNEU3TPMTALOX15TSHR
SCHEMBL13068688 0.81 KDM4D (0.40) KDM4DNEU3TPMTALOX15TSHR
SCHEMBL2259073 0.80 PTGS2 (0.41) KDM4DWDR5TPMTALOX15TSHR
SCHEMBL22999837 0.80 HPGD (0.52) MMP2KDM4EHSD17B10
SCHEMBL5586094 0.80 HCAR3 (0.44) TPMTALOX15TSHRHIF1ATTR
SCHEMBL3346035 0.79 HCAR3 (0.35) KDM4DEGLN1WDR5TPMTKMT2A
SCHEMBL476639 0.76 ALDH1A1 (0.43) TPMTALOX15TSHRHIF1APOLB
SCHEMBL18360158 0.75 HCAR3 (0.49) TPMTALOX15TSHRHIF1ATTR
SCHEMBL15295907 0.75 HCAR3 (0.49) EGLN1TPMTALOX15TSHRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225223-B1 ORGANIC COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2017-01-11 EP disclosed
US-8829006-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-09 US disclosed
US-20110195954-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-11 US disclosed
US-20110195954-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-11 US disclosed
EP-2251338-A2 Organic compounds Boehringer Ingelheim International GmbH (DE) 2010-11-17 EP disclosed
EP-2225223-A2 ORGANIC COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2010-09-08 EP disclosed
WO-2009065919-A2 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 WO disclosed
WO-2009065919-A2 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195954-A1 NOVEL COMPOUNDS CALCRL, CALCR, CALCA KDM4D 3935/4885EGLN1 4382/4885WDR5 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.